| ORIGINAL ARTICLE |
|
| Year : 2006 | Volume
: 43
| Issue : 1 | Page : 26-29 |
Squamous cell carcinoma of the maxillary sinus: A Tata Memorial Hospital experience
Sajid S Qureshi1, Devendra A Chaukar1, Sanjay D Talole2, Anil K Dcruz1
1 Department of Head and Neck Services, Tata Memorial Hospital, Parel,Mumbai - 400012, India
2 Department of Biostatistics, Tata Memorial Hospital, Parel, Mumbai - 400012, India
Correspondence Address:
Sajid S Qureshi
Department of Head and Neck Services, Tata Memorial Hospital, Parel,Mumbai - 400012
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.25772
Background: The optimal treatment of maxillary sinus carcinoma remains to be defined and there is a paucity of Indian studies on the subject. Aims: To present experience of management of squamous cell carcinoma of the maxillary sinus treated with curative intent at a single institution. Settings and Design:Retrospective study of patients with squamous cell carcinoma of the maxillary sinus who presented between 1994 to 1999. materials and Methods:The records of 73 patients with squamous cell carcinoma of the maxillary sinus were analyzed. Sixty-two patients were evaluable. Forty patients (65%) were treated with surgery followed by postoperative radiotherapy, five patients (8%) were treated with radiotherapy alone, five patients (8%) were treated with surgery alone; 12 patients (19%) received chemotherapy. Statistical analysis used: Statistical analysis was done using Kaplan-Meier method. Results: The majority of patients presented with locally advanced disease (52, 84%); nodal involvement was observed in five patients (8%). The most common site of recurrence was at the primary site, which was observed in 28 patients (45%) and regional failures occurred in 10 (16%). The 3 and 5-year overall survival was 38% and 35% and the disease free survival was 29% and 26% respectively. The 5-year overall survival after surgery and postoperative radiotherapy was 42%. Conclusions:The majority of patients present with advanced disease resulting in poor outcomes to conventional treatment modalities. Locoregional tumor progression remains a significant pattern of failure. New approaches such as neoadjuvant or concomitant chemoradiotherapy with aggressive surgery need to be considered and evaluated in prospective studies.
[FULL TEXT] [PDF]*
|
